How compounded peptide prescribing works: what a compounded peptide is and what you actually get

If you have seen a peptide offered as a “compounded prescription” and wondered what that actually means, this is the page that untangles it. “Compounded” is not a synonym for “approved,” and it is not a synonym for “research chemical” either. It describes a specific kind of pharmacy work, done for a specific patient, with its own safeguards and its own gaps. Here is how compounded prescribing works in plain English: who makes the product, what a compounded peptide prescription looks like from the patient’s side, how it differs from an FDA-approved drug, which marketing claims should make you skeptical, and what people are saying about it.

What is a compounding pharmacy, and how is it different from a drug manufacturer?

A compounding pharmacy makes a medicine for a specific patient rather than manufacturing a standardized product for the mass market. When a drug company makes Ozempic or a generic tablet, it runs the full FDA approval process: clinical trials, manufacturing review, and an approved label. The finished product holds full FDA approval, and you can accurately say so. Compounding is a different activity. A licensed pharmacist combines or alters ingredients to fill an individual prescription, often because the patient needs a dose, form, or ingredient combination that no approved product provides. That is a legitimate and long-standing part of medicine.

The catch is what compounding is not. A compounded preparation never holds FDA approval. No one ran it through trials or reviewed its specific batch. In the FDA’s own words, compounded drugs are not FDA-approved, which “means the agency does not review their safety, effectiveness or quality before they are marketed.” It is also inaccurate to describe a compounded drug as a “generic version of,” “the same as,” or otherwise equivalent to a drug the FDA has approved, because generics are approved before marketing and compounded drugs are not. Compounding buys you customization and access; it does not buy you the FDA’s review.

What are the two kinds of compounding, 503A and 503B?

Federal compounding law splits into two sections of the Food, Drug, and Cosmetic Act, and the names come straight from those section numbers. State rules sit on top of both, and PeptideAgent’s compounding pharmacy guide by state covers that layer, including the requirement that a pharmacy be licensed or registered in the state it ships to.

503A covers the traditional model: a state-licensed pharmacy or physician compounds a drug for an individual patient. The statute, 21 U.S.C. 353a, ties this kind of compounding to an “identified individual patient based on the receipt of a valid prescription order” from a licensed prescriber. This is the route almost every telehealth peptide or hormone offering runs through. The law also limits which raw ingredients, called bulk drug substances, a 503A pharmacy may start from; the FDA summarizes those conditions on its 503A bulk drug substances page.

503B covers outsourcing facilities, which compound at a larger scale, sometimes without a patient-specific prescription, and register with and are inspected by the FDA under stricter manufacturing standards. A 503B facility works from its own separate list of permitted bulk substances, or from drugs on the FDA’s shortage list at the time. That shortage exception is what let compounded semaglutide flow during the GLP-1 shortages, and the FDA clarified its policies for compounders as that supply stabilized.

For the peptides this site covers, 503A is the relevant track, because these are individualized prescriptions. That is why a compounded peptide offer almost always arrives bundled with some kind of clinical review.

What does a compounded peptide prescription look like in practice?

From the patient’s side, a compounded peptide prescription is a three-step chain: an intake, a prescriber’s decision, and a pharmacy that fills the order. Online, the intake is usually a health questionnaire, sometimes followed by a video or message consultation. A licensed clinician reviews it and decides whether to write a prescription for you as an individual patient. A pharmacy then prepares the product and ships it, labeled with your name and directions, rather than a generic “for research” sticker. If you are choosing where that intake happens, our comparison of a local peptide clinic and an online provider covers how the exam, oversight and follow-up differ.

Each link in that chain does something a “research use only” order skips. The prescriber is the person who is supposed to screen for conditions or medications that make a product a bad idea for you. The pharmacy is the party responsible for preparing an injectable under sterile-compounding standards; USP General Chapter <797> is the national standard that sets those requirements for cleanroom air, personnel training, and beyond-use dating. And the label on a dispensed product names a patient and a prescriber, so there is someone to call if something goes wrong.

It is worth being equally clear about what the chain does not do. A prescription does not turn a peptide into a studied one: the evidence for most research peptides is the same thin, mostly preclinical evidence whichever way the vial reaches you. And the quality of the chain depends on the people in it. A questionnaire that no clinician meaningfully reviews is a checkout page with extra steps, which is why our guide to how peptide telehealth works spends time on what a real review looks like.

Three questions are worth asking any provider before a compounded peptide ships. Which pharmacy prepares it, and where is that pharmacy licensed? Is an injectable made under sterile-compounding standards, and will it carry a beyond-use date? And will the label name you, the prescriber, and the directions? A provider who cannot answer those plainly is telling you something about the rest of the chain, and a provider who answers them easily has at least built the chain the way it is supposed to work.

How is a compounded peptide different from an FDA-approved drug, and why does it matter?

The difference is who has checked the product before it reaches you. An approved drug’s safety and effectiveness were reviewed before it was marketed, its manufacturing is inspected, and its label carries tested directions. A compounded drug skips that premarket review. The FDA states plainly that compounded drugs “can serve an important medical need for patients,” but that if one does not meet appropriate quality standards, “such as if a drug is contaminated or contains too much active ingredient,” it could cause serious injury or death. The same page warns that the labels on compounded drugs “may not include important information such as adequate directions,” and that the agency continues to find insanitary conditions at compounding facilities during inspections.

The reference case for how badly this can go is not hypothetical. In 2012, contaminated compounded steroid injections from a single pharmacy caused a national fungal meningitis outbreak; the CDC’s final count was 753 cases and 64 deaths (CDC, multistate fungal meningitis outbreak). That happened inside a licensed facility, which is why the sterility and inspection questions matter for compounded products too. The practical takeaway is a ladder, not a binary: an approved drug sits at the top, a properly compounded prescription sits in the middle with real but narrower safeguards, and a research-use-only vial sits at the bottom with none. Our comparison of prescribed versus gray-market peptides walks through that middle and bottom rung on sterility, dose, and identity.

Which marketing claims about compounded peptides should make you skeptical?

The FDA has published a short list of claims it considers false or misleading when telehealth companies promote compounded drugs, and it doubles as a buyer’s checklist. In its reminders to telehealth companies, written mainly about compounded GLP-1s but framed as applying to other drugs too, the agency flags:

• Branding that implies the telehealth company is the compounder when it is not. The pharmacy that actually prepares your product should be identifiable.
• “Generic version” or “same as” language that equates a compounded drug with a brand-name medicine. Generics are reviewed before marketing; compounded drugs are not.
• Claims of FDA approval or FDA evaluation for safety and effectiveness. Compounded drugs are not reviewed by the agency for safety, effectiveness, or quality before marketing.
• “Clinically proven to produce the same result” as an approved drug.
• Claims that the pharmacy itself carries FDA approval or an FDA license. The agency says it does not approve or license any compounding facility, so that phrase is wrong on its face.

If a peptide offer leans on any of those phrases, treat it the way you would treat a vendor with no certificate of analysis: as a sign that marketing is doing the work documentation should be doing.

Which peptides are actually FDA-approved drugs?

A short list of peptides are or were drugs the FDA has approved, and they show what a fully reviewed product looks like, though not for the uses peptide marketing usually targets.

• Tesamorelin, sold as Egrifta, is approved by the FDA, but only to reduce excess abdominal fat in people with HIV-associated lipodystrophy. Its label does not support general weight loss or physique use.
• Bremelanotide, sold as Vyleesi and known in peptide circles as PT-141, is approved by the FDA, but only for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
• Sermorelin, formerly sold as Geref, once carried FDA approval, but that approval was withdrawn in 2009, so it is not an approved product today and should not be described as one.

The broader lesson is that for many goals people chase peptides for, the best-studied option is not a peptide at all. In metabolic care, that means the branded GLP-1 drugs that hold full FDA approval, semaglutide as Ozempic and Wegovy and tirzepatide as Mounjaro and Zepbound. For recovery, focus, or healthy aging, the research peptides most people ask about are not FDA-approved for any use, and a compounded version of one carries the same evidence base as any other version.

What are people saying about compounded peptides?

In social-media discussion of research peptides, the compounding question comes up constantly, and the most useful thread in it is a distinction commenters keep drawing themselves. Our Community Insights summaries for this site, drawn from public posts on X in mid-July 2026, show posters across Semax, Epitalon, KPV, and DSIP threads stressing that whether a peptide can be compounded is an access question, not an approval vote and not proof that it works, and warning that headlines and markets tend to blur the two. MOTS-c threads add another angle: some community groups were gathering anonymous user reports while the compounding question was in the news. These are anecdotes, not evidence, but the point they make is the one this page makes: a compounded prescription changes who prepares and supervises a peptide, not what the research says about it.

What does all of this mean for you as a patient?

It means the right first question is not “can I get this compounded” but “what would a compounded version actually give me?” The honest answer is a prescriber who reviews you, a pharmacy responsible for sterility and labeling, and a named party if something goes wrong. It is not FDA review, and it is not new evidence. If those trade-offs fit your goal, the useful next step is to judge the specific provider and pharmacy, using the claims list above and the practical checks in how to tell if a peptide vendor is legit.

The practical, honest move is to start from your goal and a licensed provider rather than from a molecule and a vendor. A clinician can weigh which options actually fit what you are trying to achieve, whether that is an approved medication, a compounded prescription, or a different supervised therapy. Our guide on how peptide telehealth works walks through the online version of that process, and our BPC-157 buyer’s guide applies all of this to the most-searched research peptide. If you are still weighing a “research use only” source, start with what that label really means in our guide on research-use-only peptides.

Status: Most research peptides, including BPC-157 and TB-500, are not FDA-approved; some are sold by telehealth providers as a compounded prescription. See the peptide status explainer for each one.

Educational information only, not medical advice. Factual statements are sourced to the FDA, CDC, USP, statute, and drug-label records cited above and are accurate as of October 12, 2026; community themes summarize public posts and are not evidence.